• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

    18.11 +0.82 (+4.71%)
    Streaming Delayed Price Updated: 9:56 AM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 105,153
    Open 17.45
    Bid (Size) 17.98 (300)
    Ask (Size) 18.23 (400)
    Prev. Close 17.29
    Today's Range 17.45 - 18.23
    52wk Range 4.610 - 24.27
    Shares Outstanding 96,008,951
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Appoints Ron Philip to Board of Directors
    From Avalo Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +6.4%
    +6.4%
    1 Month
    +15.0%
    +15.0%
    3 Month
    +8.4%
    +8.4%
    6 Month
    -0.3%
    -0.3%
    1 Year
    +274.1%
    +274.1%

    More News

    Read More
    News headline image
    Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results ↗
    Via Benzinga
    Wednesday's session: gap up and gap down stocks ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Avalo Therapeutics Announces Pricing of $375 Million Public Offering
    From Avalo Therapeutics
    Via GlobeNewswire
    Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
    Via Chartmill
    News headline image
    Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Purchases Optional Milestone Buyout
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics to Participate in Upcoming Investor Conferences
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics to Participate in Upcoming Investor Conferences
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics to Participate in Upcoming Investor Conferences
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug ↗
    Via Stocktwits
    News headline image
    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga

    Frequently Asked Questions

    Is Avalo Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Avalo Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Avalo Therapeutics, Inc. - Common Stock trade on?
    Avalo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Avalo Therapeutics, Inc. - Common Stock?
    The ticker symbol for Avalo Therapeutics, Inc. - Common Stock is AVTX on the Nasdaq Stock Market
    What is the current price of Avalo Therapeutics, Inc. - Common Stock?
    The current price of Avalo Therapeutics, Inc. - Common Stock is 18.11
    When was Avalo Therapeutics, Inc. - Common Stock last traded?
    The last trade of Avalo Therapeutics, Inc. - Common Stock was at 07/02/26 09:56 AM ET
    What is the market capitalization of Avalo Therapeutics, Inc. - Common Stock?
    The market capitalization of Avalo Therapeutics, Inc. - Common Stock is 1.74B
    How many shares of Avalo Therapeutics, Inc. - Common Stock are outstanding?
    Avalo Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.